Ready to submit
Late-Breaking Clinical Trials
Call for Late-Breaking Clinical Trials (LBCT)
The QICC 2026 Late-Breaking Clinical Trials (LBCT) Forum invites unpublished, high-impact cardiovascular clinical studies with significant scientific merit and clinical impact. Accepted LBCT submissions will be considered for simultaneous full-text publication in JACC or its leading subspecialty journals.
Present groundbreaking cardiovascular research on a global stage
The QICC 2026 Late-Breaking Clinical Trials (LBCT) Forum invites unpublished, high-impact cardiovascular clinical studies with significant scientific merit and clinical impact. Accepted LBCT submissions will be considered for simultaneous full-text publication in JACC or its leading subspecialty journals.
4Submission types
OnlineOfficial submission system
QICC2026 Hangzhou presentation
Notice
Call for Late-Breaking Clinical Trials (LBCT)
The Late-Breaking Clinical Trials (LBCT) Forum is dedicated to presenting groundbreaking cardiovascular research with significant scientific merit and clinical impact. In collaboration with JACC and its premier sister journals, QICC 2026 invites global researchers to submit their most compelling clinical studies in cardiovascular medicine.
Accepted LBCT submissions will be considered for simultaneous full-text publication in JACC or its leading subspecialty journals.
https://www.qiccmd.com/sub/Submission Website
August 1, 2026Submission Deadline
November 19-22, 2026Conference Dates
Guidelines
Submission Guidelines
We welcome unpublished, high-impact clinical studies, including pivotal trials, prospective randomized controlled trials, multicenter registries and other cardiovascular clinical studies that meet the following criteria.
First Disclosure
The primary endpoint or important secondary endpoint results are planned for first presentation at QICC 2026.
No Prior Publication
The study has not been publicly published before QICC 2026.
LBCT Forum Presentation
Accepted studies will be invited for presentation at the QICC 2026 Late-Breaking Clinical Trials Forum.
Completion Confirmation
Submission indicates that the investigator confirms the study is nearing completion. Positive and negative results are equally eligible.
Key Features
Key Features
Considered for JACC publication
Outstanding accepted studies may be recommended for simultaneous full-text publication in JACC or its leading subspecialty journals after review.
International peer review
Your research logic will be examined by leading experts and journal reviewers, helping high-quality clinical evidence reach a broader audience.
Global first-presentation platform
Selected studies will be presented before cardiovascular experts from China and abroad at QICC 2026.
Submission
Submission Method and Contacts
To facilitate submission, revision and timely access to acceptance and scheduling information, the conference accepts online submissions only. Email and postal submissions are not accepted. Please complete the online form through the official submission system.
General InquiriesMs. Liu Shanshan +86 195 6048 0875
Technical SupportMr. Feng +86 186 1006 5085
Emailsub@qiccmd.com
Enter Submission System